| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/1000-1/5000 | Human,Mouse,Rat |
| Aliases | B7DC; Btdc; PDL2; CD273; PD-L2; PDCD1L2; bA574F11.2 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Fusion protein of human PDCD1LG2 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于PDCD1LG2(PD-L2)抗体的模拟参考文献示例(实际文献需通过学术数据库检索)：
---
1. **文献名称**：*Development of a PDCD1LG2-Specific Antibody for Enhanced Cancer Immunotherapy*
**作者**：Chen X, et al.
**摘要**：研究团队开发了一种高亲和力抗PDCD1LG2单克隆抗体，证实其可通过阻断PD-1/PD-L2通路显著增强T细胞杀伤活性，并在黑色素瘤小鼠模型中抑制肿瘤进展，且毒性较低。
2. **文献名称**：*PD-L2 Blockade Reshapes the Tumor Microenvironment and Synergizes with Anti-PD-1 Therapy*
**作者**：Rodriguez-Abreu D, et al.
**摘要**：本文发现PDCD1LG2抗体单药治疗可逆转肿瘤相关巨噬细胞的免疫抑制表型，与抗PD-1联用后显著提高疗效，为联合免疫治疗策略提供实验依据。
3. **文献名称**：*Structural Characterization of PDCD1LG2 and Its Interaction with Therapeutic Antibodies*
**作者**：Tan S, et al.
**摘要**：通过冷冻电镜解析PDCD1LG2的蛋白结构及与抗体的结合表位，揭示抗体作用机制，为优化抗体药物设计提供结构生物学基础。
4. **文献名称**：*Biomarker-Driven Clinical Trial of Anti-PD-L2 Antibody in Advanced Solid Tumors*
**作者**：Nishino M, et al.
**摘要**：一项Ⅰ期临床试验评估了抗PDCD1LG2抗体在PD-L2高表达实体瘤患者中的安全性及初步疗效，显示部分患者达到持久缓解，且耐受性良好。
---
**提示**：以上为模拟示例，建议通过PubMed、Web of Science等平台检索真实文献(关键词：PDCD1LG2、PD-L2、antibody、immunotherapy)。
The PDCD1LG2 antibody targets PDCD1LG2 (Programmed Cell Death 1 Ligand 2), also known as PD-L2. a cell surface protein belonging to the B7 family of immune checkpoint molecules. PD-L2 binds to the PD-1 receptor on T cells, delivering inhibitory signals that suppress T-cell activation and promote immune tolerance. While structurally similar to PD-L1 (PDCD1L1), PD-L2 exhibits a more restricted expression pattern, primarily found on antigen-presenting cells (e.g., dendritic cells, macrophages) and some tumor cells. Its role in immune evasion has made it a focus in cancer immunotherapy research.
PDCD1LG2 antibodies are designed to block PD-L2/PD-1 interactions, potentially restoring T-cell-mediated antitumor immunity. However, therapeutic interest in PD-L2 has been less prominent compared to PD-L1. partly due to its narrower expression and overlapping functions with PD-L1. Recent studies suggest PD-L2 may have distinct roles in specific cancers or immune contexts, such as modulating Th2 responses or influencing resistance to PD-1/PD-L1 inhibitors. Research tools like PDCD1LG2 antibodies are critical for elucidating its biology, while therapeutic antibodies remain exploratory, with some in preclinical development. Understanding PD-L2's dual roles—both as an immune checkpoint and a regulator of tissue homeostasis—could uncover new avenues for combination therapies or biomarkers in oncology and autoimmune diseases.
×
